
Affinia Therapeutics Presents New Data on its Lead AFTX-201 Program in BAG3 Dilated Cardiomyopathy, BBB-Penetrant AAV Capsids, and Proprietary Manufacturing Technology at the 28 th American Society of Gene & Cell Therapy 2025 Annual Meeting
WALTHAM, Mass.--(BUSINESS WIRE)--Affinia Therapeutics ('Affinia'), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies for devastating cardiovascular and neurological diseases, today announced the presentation of new preclinical data on AFTX-201, its lead program for BAG3 dilated cardiomyopathy (DCM), as well as its novel AAV capsids for diseases of the central nervous system (CNS), and the company's high-yield manufacturing process. This research will be presented in several oral and poster sessions at the 28 th American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting, being held May 13-17, 2025 in New Orleans, LA and virtually.
Affinia has rationally designed novel capsids and gene therapies with increased tropism for cardiac muscle, skeletal muscle, or CNS and more uniform tissue distribution than AAV9. This improved biodistribution is attained at doses that are greater than 10-fold lower than those used with conventional capsids such as AAV9 while detargeting the liver and dorsal root ganglia, both potential sites of toxicity. Furthermore, Affinia has developed a proprietary plasmid design system that results in multi-fold improvement in manufacturing yields across a range of novel and conventional capsids and payloads.
New AFTX-201 data featured at ASGCT 2025
AFTX-201, a potential first-in-class and best-in-class investigational gene therapy intended to be given as a simple one-time intravenous administration, is designed to treat BAG3-associated dilated cardiomyopathy (DCM) using a novel cardiotropic capsid engineered for efficient and selective cardiac transduction at low doses. New data show that in BAG3 haploinsufficient mice, AFTX-201 restored cardiac function and showed a favorable safety profile, and in nonhuman primates (NHPs), achieved robust cardiomyocyte BAG3 expression with a favorable safety profile. These data will be featured in a poster entitled, 'A Novel Investigational AAV Gene Therapy for Treatment of BAG3 Dilated Cardiomyopathy,' being presented by Giri Murlidharan, Ph.D., Senior Director, Vector Translational Biology at Affinia, on Wednesday, May 14, 2025, 5:30-7:00 pm CT (Poster Hall 12; abstract AMA1161).
'BAG3 DCM represents a significant unmet medical need as patients experience a rapidly progressive cardiac dysfunction and there is no treatment that exists which targets the underlying mechanism of disease,' said Hideo Makimura, M.D., Ph.D., Chief Medical Officer at Affinia. 'AFTX-201 is a potential first-in-class and best-in-class investigational gene therapy using a novel cardiotropic capsid. AFTX-201 addresses the genetic root cause of BAG3 DCM and in preclinical studies has shown highly differentiated efficacy and an improved safety profile as compared with a gene therapy construct using a conventional AAV capsid. These findings support clinical advancement of AFTX-201, with a Phase 1/2 trial, the UPBEAT trial, planned to assess safety, tolerability, and pharmacodynamics in patients with BAG3 DCM. Endpoints that have demonstrated efficacy in as early as one-to-three months post dose in prior studies for other cardiovascular drugs and diseases will be explored in the upcoming study.'
AFTX-201 is undergoing investigational new drug (IND)-enabling studies. Affinia has completed a successful pre-IND meeting with the U.S. Food and Drug Administration (FDA) and plans to file an IND in the fourth quarter of 2025 with potential initial readouts of clinical trial safety and efficacy in the first half of 2026.
Data on Affinia's high-yield manufacturing and CNS capsids at ASGCT
Affinia's flexible, high-yielding, and scalable process developed for the production of AFTX-201 will be featured in an oral presentation. Using Design of Experiment (DoE) optimization, the upstream process achieved a yield exceeding 3e15 vg/L at 50L scale, supported by a streamlined downstream process including single-use clarification, affinity purification, and CsCl ultracentrifugation resulting in a high-quality product with more than 90% full capsid enrichment. The process was successfully transferred to Affinia's Contract Development and Manufacturing Organization (CDMO) partner with results replicated. The product has shown stability for more than six months, with ongoing monitoring for extended time points. Additionally, the high yields enabled a reduction in Toxicology and Clinical lot production scale from 250L to 50L, resulting in significant cost savings. The presentation, 'Development of a Flexible High Yielding, High Performing Process for Manufacturing of AFTX-201, a Novel Investigational AAV Gene Therapy for Treatment of BAG3 Dilated Cardiomyopathy,' will be presented by Matt Edwards, MBA, Vice President of Process Science at Affinia, on Friday, May 16, 2025 at 4:45-5:00 pm CT (Room 288-290; abstract AMA1147).
Rob May, Affinia's Chief Technical Operations Officer, said, 'We are pleased with the successful technology transfer to our CDMO partner and are progressing toward the manufacture of GMP lots. We have demonstrated that Affinia's proprietary high-yield manufacturing process delivers high-quality, stable product and enables reduced production scale and significant cost efficiency.'
New data will be presented on Affinia's proprietary plasmid design system that significantly improves adeno-associated virus (AAV) manufacturing yields and packaging efficiency across both wild-type and novel capsids. This system enables greater than 10-fold increase in vector genome yield and up to four-fold improvement in the percentage of full capsids at harvest, reducing upstream batch size and downstream purification burden. Implementation within Affinia's Vector Core in 2024 resulted in a 740% increase in R&D vector titers and yields exceeding 5e15 vg/L for programs, offering substantial cost and efficiency gains for both discovery and clinical manufacturing. These data will be featured in a poster entitled, 'High-Yield, Pan-Serotype Plasmid System for Manufacturing Adeno-Associated Virus Gene Therapies: Cost and Efficiency Benefits for R&D and Commercial Processes,' being presented today, Tuesday, May 13, 2025, at 6:00-7:30 pm CT by Mr. Edwards (Poster Hall 12; abstract 1150).
Affinia will also present data on its engineered capsids that target receptor-Y, a novel human brain receptor, to enable AAV crossing of the blood-brain barrier. Capsids were identified with the ability to bind both human and nonhuman primate (NHP) orthologs of this receptor in vitro. An initial screen of 13,000 Gen1 in vitro hits in NHPs using intravenous dosing revealed that a minority of capsids that bind the receptor protein in vivo actually have in vivo functionality. Affinia reports the results of screening in NHPs a Gen2 library of 50,000 capsids that built upon the Gen1 in vivo hits in a poster entitled, 'Engineered AAV Capsids That Target a Novel Human Brain Endothelial Receptor Achieve Robust Transduction in Nonhuman Primate Central Nervous System After Intravenous Dosing.' The poster is being presented by John Reece-Hoyes, Ph.D., Senior Director, Head of Vector Biology at Affinia, on Thursday, May 15, 2025, 5:30-7:00 pm CT (Poster Hall 12; abstract AMA1256).
'Compared to AAV9, the leading Gen2 hits achieved several orders of magnitude higher mRNA expression across NHP cortical and deep brain regions,' said Charles Albright, Ph.D., Affinia's Chief Scientific Officer. 'Affinia's capsids that target receptor-Y are highly differentiated from conventional AAVs being used in CNS programs currently in clinical trials. Studies generating clonal biodistribution and mechanistic data for Gen2 leads are currently underway."
Abstracts can be found at https://annualmeeting.asgct.org/.
About Affinia Therapeutics
Affinia Therapeutics is pioneering a new class of rationally designed gene therapies that treat rare and prevalent diseases. Affinia Therapeutics' pipeline of first-in-class or best-in-class product candidates in cardiovascular and neurological diseases leverages its proprietary next-generation capsids, payloads, or manufacturing approaches and have shown efficacy, safety, and differentiation in relevant animal models. For more information, visit https://www.affiniatx.com.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
an hour ago
- Business Wire
DigitalOcean and AMD Collaborate to Advance AI Using Cloud-Based GPUs
NEW YORK--(BUSINESS WIRE)-- DigitalOcean Holdings, Inc. (NYSE: DOCN), the simplest scalable cloud for digital native enterprises, today announced a collaboration with AMD that provides DigitalOcean customers with access to AMD Instinct™ GPUs as DigitalOcean GPU Droplets to power their AI workloads starting with the AMD MI300X GPUs. Later this year, DigitalOcean will offer AMD Instinct™ MI325X GPUs, further expanding access to powerful and affordable GPU models. AMD Instinct™ MI325X GPU accelerators set new AI performance standards, delivering incredible performance and efficiency for training and inference. AMD Instinct MI300X GPUs deliver leadership performance for accelerated high-performance computing (HPC) applications and the newly exploding demands of generative AI. With the AMD ROCm™ software platform, customers can develop powerful HPC and AI production-ready systems faster than ever before. Its large memory capacity allows it to hold models with hundreds of billions of parameters entirely in memory, reducing the need for model splitting across multiple GPUs. By combining powerful AMD AI compute engines and DigitalOcean's cloud technologies, the collaboration aims to empower the massive community of digital native enterprises to integrate AI into their applications and support the most demanding AI workloads at scale. These next-generation GPUs have already been available in bare metal configurations for customers seeking increased control and computing power. These GPUs are now also available as GPU Droplets or as DigitalOcean Kubernetes worker nodes. The GPU Droplets are available both as single and eight GPU configurations, allowing customers to optimize costs for their specific use cases. Accessing these GPU Droplets through DigitalOcean offers several key benefits, including competitive pricing at $1.99/GPU per hour, a simple setup process, and enterprise-grade SLAs. While other cloud providers require multiple steps and deep technical knowledge to configure security, storage, and network requirements, DigitalOcean's GPU Droplets can be set up with just a few clicks. In addition to these new GPUs, customers will also have access to AMD Developer Cloud, a new platform powered by DigitalOcean that is purpose-built for rapid, high-performance AI development. Customers will have access to a fully managed environment that provides instant access to AMD Instinct MI300X GPUs—with zero hardware investment or local setup required. Whether fine-tuning LLMs, benchmarking inference performance, or building a scalable inference stack, the AMD Developer Cloud provides the tools and flexibility to get started instantly—and grow without limits. 'DigitalOcean's collaboration with AMD is another proof point to make AI easily accessible to our customers,' said Bratin Saha, Chief Product & Technology Officer at DigitalOcean. 'With access to AMD GPUs, DigitalOcean customers have an extensive portfolio of GPUs with the flexibility of the computing configuration that best suits their requirements.' "At AMD, we are proud to work with DigitalOcean to provide developers with cutting-edge solutions for developer enablement and demanding workloads that require large amounts of memory,' said Negin Oliver, corporate vice president of business development, Data Center GPU Business, at AMD. 'Together, AMD and DigitalOcean are committed to providing the critical innovative technologies required to support the evolving needs of growing tech businesses.' To access AMD Instinct GPUs with DigitalOcean, visit the DigitalOcean website. DigitalOcean is the simplest scalable cloud platform that democratizes cloud and AI for digital native enterprises around the world. Our mission is to simplify cloud computing and AI to allow builders to spend more time creating software that changes the world. More than 600,000 customers trust DigitalOcean to deliver the cloud, AI, and ML infrastructure they need to build and scale their organizations. To learn more about DigitalOcean, visit


Business Wire
an hour ago
- Business Wire
Rosen Law Firm Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public. So What: If you purchased GeneDx securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. What to do next: To join the prospective class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@ for information on the class action. What is this about: On February 5, 2025, Grizzly Research published a report entitled 'Insiders Attest that GeneDx (Nasdaq: WGS) Is Actively Committing Widespread Fraud.' This report stated that Grizzly believed that GeneDx's 'growth is largely an illusion, driven by fraudulent schemes and illegal tactics deliberately aimed at exploiting Medicaid and Medicare systems to artificially inflate revenue.' On this news, GeneDx stock fell 6.7% on February 5, 2025. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. At the time, Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone, the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by Law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome.


Business Wire
an hour ago
- Business Wire
InPlay Unveils 2nd-Gen NanoBeacon IN120 SoC: Unlocking Game-Changing Efficiency for Smart Label Makers with Integrated Temperature Sensor!
IRVINE, Calif.--(BUSINESS WIRE)--InPlay Inc., a leader in ultra-low-power wireless SoC technologies, announces the upcoming release of its revolutionary second-generation NanoBeacon System-on-Chip (SoC), the IN120. Specifically engineered for high-volume smart label applications, the IN120 delivers unprecedented simplicity, cost savings, and manufacturing efficiency. "By reducing external components to just one, we've enabled manufacturers to produce smart labels more efficiently and economically—opening the door to broader deployment in logistics, pharmaceuticals, and disposable asset tracking." Share The IN120 features an ultra-minimalist design, requiring only one external component—a 26MHz crystal. This design innovation dramatically reduces complexity, enabling significant savings in assembly time, manufacturing costs, and supply chain logistics. Delivered in a bumped wafer Known Good Die (KGD) format, the IN120 integrates effortlessly into existing roll-to-roll RFID inlay manufacturing processes, minimizing the need for new capital investments. A key highlight of the IN120 is its integrated precision temperature sensor (±1°C accuracy), eliminating the need for an external temperature sensing component typically required in cold chain monitoring and logistics applications. This integrated approach not only lowers component costs but also enhances reliability and simplifies production processes. "Our new IN120 SoC sets a benchmark for smart label technology," said Jason Wu, Cofounder and CEO of InPlay Inc. "By reducing external components to just one, we have enabled manufacturers to produce smart labels more efficiently and economically, opening the door to broader deployment in logistics, pharmaceuticals, and disposable asset tracking." Further elevating its practicality, the IN120 supports a broad voltage range from 1.1V to 3.6V, compatible with virtually all battery types, including cost-effective printable batteries (1.5V per cell). This flexibility significantly reduces the cost and footprint of smart labels, making disposable, thin-form-factor solutions economically feasible at high volumes. InPlay also offers preprogramming services for the IN120, streamlining the manufacturing workflow and dramatically cutting production setup times, further amplifying operational efficiency for manufacturers. The IN120 is poised to transform smart label applications by significantly lowering barriers related to cost, complexity, and production speed, making active smart labels as economically viable as passive RFID labels, but with vastly superior functionality. The IN120 SoC will be available for sampling starting Q1'2026, with mass production planned shortly thereafter. InPlay Inc. is a pioneering technology company specializing in the development of advanced wireless communication solutions for the IIoT market. Our products are designed to deliver high performance, ultra-low power consumption, and robust security, addressing the most demanding requirements of industrial and consumer applications.